

## Strategic priorities for the OECI

### Quality improvement in Cancer Care and Research

The Accreditation and Designation Programme, specifically designed for cancer centres, aims to constantly improve our cancer centres' outcomes for patients and their experience of care. Although physicians, nurses and researchers constitute the core of cancer care and research, multidisciplinary working, efficient logistics and state of the art, complex infrastructure are needed in order to deliver high quality care to cancer patients. About half of the OECI Members are already included in the A&D Programme, and the present pipeline of applications indicates a steep growth in the programme, extending beyond Europe to centres in Asia and South America. The OECI quality approach is now recognised as the only existing programme specifically designed for cancer centres right across Europe (and certified by the International Society for Quality in Healthcare) providing a significant impact on the quality of cancer care and integration with translational research. The certified centres represent the so-called "OECI Quality Network". Future impact in Europe will include publications of the Programme's experience from ten years of quality assurance and improvement work, policy documents on networks, and establishing core standards for cancer care across the EU.

### Patient Involvement and Partnerships

Quality improvement in cancer care and research is a major goal shared by healthcare professionals, researchers and patients. Today, innovative cancer centres are taking initiatives, involving patients and launching collaborations with local and national patient organisations. The OECI Collaborations for Good Practices with Patients (CGPP) Working Group is evaluating, promoting and launching a wide range of projects involving patients and patient organisations. Thanks to a fruitful alliance with the European Cancer Patient Coalition (ECPC), the OECI is supporting cancer centres in their mission to fulfill today's cancer patients' expectations.

### Biobanks and Molecular Pathobiology

The OECI Biobanks and Molecular Pathobiology Working Group, together with some of the major European cancer Societies/Organisations, contributes to the continuous evolution of molecular oncology to guarantee the reproducibility of analytical methods. The WG develops specific recommendations for standardisation and validation of biomarkers and molecular analysis other than solid and liquid tissues biobanking for a better reproducible use. In order to accelerate the production of new effective protocols of treatment, a study aiming to a practical adoption of N-trials is under development. The WG collaborates with the OECI Accreditation and Designation Programme for a continuous update of the standards to be adopted. The OECI Pathology Day is the main annual event organised by this WG.

### Cancer Outcomes Research

The Cancer Outcomes Research Working Group has been activated in response to the need of following-up prospectively cohorts of patients. For CCCs located in areas covered by population registries, comparative analyses between population and clinical sets of patients will be possible, using EURO CARE and High Resolution data on survival and outcomes.

### OECI and rare cancers

OECI is particularly involved in the care of patients suffering from rare cancers. An even higher discrepancy in patient outcomes, depending on where they are treated, is still observed. OECI coordinates the work package on quality of care of the Joint Action on Rare Cancers, recently launched by the Directorate General for Health and Consumer Protection of the European Commission. OECI also acts as associate partner and facilitator of the European Reference Network on rare solid tumours in adults, an impressive network of cancer centres of reference for rare cancers that is partially based on OECI quality standards. The network, coordinated by the Centre Léon Bérard in Lyon, involves several cancer centres from 18 countries, with a large percentage coming from OECI membership.

### Supportive and Palliative care










The Supportive and Palliative Care Working Group aims to improve the quality of life of cancer patients and their families, helping them to cope with the illness and live as actively as possible by preventing and treating physical, psychosocial and spiritual suffering. The WG intends to share a common vision of early modern integrated palliative and supportive care. At the same time, it develops appropriate quality indicators and standards for care service in the OECI member institutes and it implements clinical and health service research projects through the OECI network of palliative care units in collaboration with other European networks of palliative care.


### Communication and Dissemination

The OECI Communication and Dissemination activities edited by the Liaison Office guarantee the visibility of the OECI initiatives and the participation of the Members and other interested Parties to the main initiatives.

The Liaison Office collaborates with ecanermedicalscience, the official OECI Journal. The digital and printed versions of the OECI Magazine, the Leaflet, the Yearbook and other scientific articles are the main OECI publications, along with the OECI website.

## The OECI Board






 <b>President</b> <b>Thierry Philip</b> Paris, France	 <b>Past President</b> <b>Dominique de Valeriola</b> Brussels, Belgium	 <b>Executive Secretary</b> <b>José Maria Laranja Pontes</b> Porto, Portugal
 <b>Treasurer</b> <b>Manuel Llombart Fuertes</b> Valencia, Spain	 <b>Elected Member</b> <b>Carlos Caldas</b> Cambridge, United Kingdom	 <b>Elected Member</b> <b>József Lövey</b> Budapest, Hungary
 <b>Elected Member</b> <b>Gunnar Sæter</b> Oslo, Norway	 <b>Elected Member</b> <b>Marien van der Meer</b> Amsterdam, The Netherlands	 <b>Elected Member</b> <b>Giovanni Apolone</b> Milan, Italy

 <b>OECI Director</b> <b>Claudio Lombardo</b> Brussels, Belgium - Genoa, Italy	 <b>OECI Central Office</b> <b>Guy Storme</b> Brussels, Belgium
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------

## Accreditation and Designation Programme

 <b>ACCREDITATION AND DESIGNATION PROGRAMME</b>	 <b>ISQua</b> STANDARDS	 <b>OECI COMPREHENSIVE Cancer Centre</b>	 <b>OECI CLINICAL Cancer Centre</b>	 <b>Simon Oberst</b> Cambridge, United Kingdom
---------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------

## Working Groups

 <b>Biobanks and Molecular Pathobiology</b> <b>Giorgio Stanta</b> Trieste, Italy	 <b>Supportive and Palliative Care</b> <b>Tiina Hannele Saarto</b> Helsinki, Finland
 <b>Cancer Economics and Benchmarking</b> <b>Wim H. van Harten</b> Amsterdam, The Netherlands	 <b>Collaboration for Good Practices with Patients</b> <b>Dominique de Valeriola</b> Brussels, Belgium
 <b>Cancer Outcomes Research</b> <b>Milena Sant</b> Milan, Italy	

OECI-EEIG Central Office - c/o Fondation Universitaire - 11, Rue d'Egmont  
Phone: +32 2 512 0146, B-1000 Brussels, Belgium

May 2019



Organisation  
of European  
Cancer Institutes

ecancermedicalscience

Official OECI Journal

DEVELOPING  
THE FUTURE IN  
COMPREHENSIVE  
CANCER CARE

www.oeci.eu  
oeci@oeci.eu

ONE MORE REASON  
TO JOIN THE OECI  
IS CERTIFYING  
YOUR QUALITY  
IN ONCOLOGY!

## OECI Objectives

The OECI aims to promote efficient partnership, reduce fragmentation and increase competitiveness amongst European cancer centres and institutes.

This goal is being achieved by promoting and enhancing the concept of "comprehensiveness" and "multi-disciplinarity", supporting quality in cancer care and dynamically working in crosscut expertise by involving our Working Groups, our Members and promoting synergies with other cancer Organisations.

The OECI is currently geared towards creating a "network of cancer networks" where primary prevention, screening & early diagnosis, basic, translational & clinical research, collaboration for good practices with patients, biobanks and pathobiology, supportive and palliative care, cancer economics and centralising real-life cancer patient data are included. The above goal is part of the Presidential proposal of an OECI evolution that may better answer to the need to work on a European Cancer Mission within the incoming Framework Programme "Horizon Europe".

The OECI aim is to accelerate the application of multidisciplinary personalised care approaches, to reduce morbidity and to guarantee an equitable access to care to all cancer patients, avoiding the collapse of the National Health Systems all over Europe.

Thierry Philip  
OECI President



“The OECI is a non-governmental, non-profit Organisation founded in Vienna in 1979 and remodeled in 2005 into OECI-EEIG, a European Economic Interest Grouping. Today, the OECI regroups 93 Members, which include some of the most prominent European Comprehensive Cancer Centres. Several major cancer centres from the Russian Federation, Turkey, Ukraine and Latin America are also members of our Organisation in order to benefit from our Accreditation and Designation Programme”



## OECl NETWORK 2019

### Austria

- Comprehensive Cancer Center Graz, Graz
- Comprehensive Cancer Center Vienna, Vienna

### Belgium

- ★ Institut Jules Bordet (IJB), Brussels
- ★ Oncologisch Centrum UZBrussel, Brussels
- ★ AZ Groeninge, Kortrijk
- Institut Roi Albert II Cliniques universitaires Saint-Luc, Brussels



### Chile

- Instituto Oncológico Fundación Arturo López Pérez (FALP), Santiago

### Colombia

- Instituto Nacional de Cancerología – ESE, Bogotá

### Croatia

- Klinika za tumore Klinicki bolnicki centar Sestre milosrdnice, Zagreb

### Czech Republic

- ★ Masarykův onkologický ústav, Brno
- Institut biostatistiky a analýz Lékařská fakulta Masarykovy univerzity, Brno



### Denmark

- ★ Vejle Sygehus, Patienternes Kræftsygehus en del af Sygehus Lillebælt, Vejle
- Kræftens Bekæmpelse Center for Kræftforskning, Copenhagen



### Estonia

- ★ Sihtasutus Tartu Ülikooli Kliinikum, Tartu
- North Estonia Medical Centre, Tallin



### Finland

- ★ HUS Syöpäkeskus Helsingin Yliopistollinen Sairaala, Helsinki
- ★ TYKS Syöpäkeskus Turun Yliopistollinen Sairaala, Turku



- ★ TAYS Syöpäkeskus Tampereen Yliopistollinen Sairaala, Tampere
- KYS Syöpäkeskus Kuopion Yliopistollinen Sairaala, Kuopio
- OYS Oulun Yliopistollinen Sairaala, Oulu

### France

- ★ Centre Léon Bérard, Lyon
- ★ Institut Curie, Paris
- ★ Institut Paoli – Calmettes, Marseille
- ★ Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse
- ★ Centre François Baclesse, Caen
- Gustave Roussy, Villejuif
- Centre de Lutte Contre le Cancer Paul Strauss, Strasbourg
- Centre Jean Perrin, Clermont-Ferrand
- Institut du Cancer de Montpellier (ICM), Montpellier
- Institut Jean-Godinot, Reims
- Institut de cancérologie des Hospices Civils de Lyon, Lyon
- APHP-CARPEN Institute and Assistance Publique Hôpitaux de Paris APHP-IUC, Paris
- Centre Henri Becquerel, Rouen



### Germany

- Deutsches Krebsforschungszentrum (DKFZ), Heidelberg
- Universitäts KrebsCentrum Dresden, Dresden
- Charité Comprehensive Cancer Center, Berlin



### Hungary

- ★ Országos Onkológiai Intézet, Budapest
- Országos Korányi TBC és Pulmonológiai Intézet, Budapest

### Ireland

- ★ Trinity St. James's Cancer Institute, Dublin

### Italy

- ★ Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano
- ★ IRCCS Azienda Ospedaliera Universitaria San Martino IST - Istituto Nazionale per la Ricerca sul Cancro, Genova
- ★ Istituto Europeo di Oncologia, Milano
- ★ Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano
- ★ Istituto Nazionale Tumori Regina Elena, Roma
- ★ Istituto Oncologico Veneto IRCCS-IOV, Padova
- ★ IRCCS Istituto Clinico Humanitas, Rozzano (Milano)
- ★ Istituto Tumori Giovanni Paolo II, Istituto di Ricovero e Cura a Carattere Scientifico, Bari
- ★ Istituto Nazionale Tumori IRCCS "Fondazione G.Pascale" (INT-Pascale), Napoli
- ★ IRCCS, Centro di Riferimento Oncologico della Basilicata (CROB), Rionero in Vulture (Potenza)
- ★ Azienda Unità Sanitaria Locale di Reggio Emilia - IRCCS Istituto in Tecnologie Avanzate e Modelli Assistenziali in Oncologia, Reggio Emilia
- Ospedale San Raffaele (OSR), Milano
- European School of Oncology (ESO), Milano
- Fondazione IFOM - FIRC Institute of Molecular Oncology, Milano



- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori [IRST]-IRCCS, Meldola (Forlì-Cesena)
- Istituto di Candiolo FPO-IRCCS, Candiolo (Torino)
- Istituto Oncologico del Mediterraneo (IOM), Viagrande (Catania)
- IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milano
- Ente Ospedaliero Ospedali Galliera, Genova
- Istituto Dermatologico San Gallicano, Roma

### Lithuania

- ★ National Cancer Institute, Vilnius

### Norway

- ★ Oslo Universitetssykehus (OUS), Oslo

### Poland

- Wielkopolskie Centrum Onkologii, Poznań

### Portugal

- ★ Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. (IPO-Porto), Porto
- ★ Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPO-Lisboa), Lisbon
- ★ Instituto Português de Oncologia de Coimbra Francisco Gentil, E.P.E. (IPO-Coimbra), Coimbra

### Romania

- ★ The "Prof. Dr. Ion Chiricuta" Institute of Oncology (IOCN), Cluj-Napoca
- SC RTC Radiology Therapeutic Center – Amethyst Radiotherapy, Otopeni

### Russia Federation

- Tatarstan Cancer Center "TCC", Kazan
- N.N. Blokhin Russian Cancer Research Centre, Moscow



- National Medical Research Radiological Centre (NMRRC), Moscow

### Serbia

- Oncology Institute of Vojvodina, Sremska Kamenica

### Slovakia

- Ústav experimentálnej onkológie SAV, Bratislava

### Slovenia

- Onkološki Inštitut Ljubljana, Ljubljana

### Spain

- ★ Fundación Instituto Valenciano de Oncología IVO, Valencia
- Institut Català d'Oncologia ICO, L'Hospitalet de Llobregat (Barcelona)

### Sweden

- ★ Karolinska Institute and University Hospital, Stockholm
- Skånes Universitetssjukhus, Lund
- Uppsala University Hospital, Uppsala

### Switzerland

- Comprehensive Cancer Center Zürich (CCCZ), Zürich

### The Netherlands

- ★ Netherlands Cancer Institute, Amsterdam
- ★ Maastricht University Medical Centre, Maastricht
- Erasmus MC Cancer Institute, Rotterdam
- IKNL Integraal Kankercentrum Nederland, Utrecht
- Radboudumc Centrum voor Oncologie, Nijmegen
- Rijnstate, Arnhem
- University Medical Center Groningen Comprehensive Cancer Center (UMCG-CCC), Groningen

### Turkey

- ★ Anadolu Sağlık Merkezi, Kocaeli
- Dokuz Eylül Üniversitesi Onkoloji Enstitüsü, Izmir



### Ukraine

- RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of National Academy of Sciences of Ukraine (IEPOR), Kyiv

### United Kingdom

- ★ The Christie NHS Foundation Trust, Manchester
- ★ Cambridge Cancer Centre, Cambridge
- ★ King's Health Partners Integrated Cancer Centre, London
- Imperial College Healthcare NHS Trust, London



### The OECl Quality Network

- ★ OECl Members A&D certified Comprehensive Cancer Centre
- ★ OECl Members A&D certified Clinical Cancer Centre
- ★ OECl Members in the A&D process
- Other OECl Members

